

An abstract geometric composition on a dark navy blue background. On the left, a vertical cream-colored rectangle is divided by a thin teal line, with two horizontal teal lines intersecting it at points marked by small teal dots. To the right of this, a large teal shape is composed of several geometric parts: a large rectangle on the right, a trapezoid below it, and a triangular section at the bottom. A thin white vertical line runs down the center of the teal shape, ending in a small teal circle. The word "Australia" is written in a white, sans-serif font in the upper right area.

Australia

Australia

Understanding the applicable framework

Medicines Australia Edition 20 took effect in March 2025. It covers patient engagement, public information, support programmes and transparency. Medicines Australia describes promotional registration conditions and member commitments; do not assume every non-promotional provision applies identically to all non-members (Medicines Australia, 2025, n.d.-a, n.d.-b).

Establish applicable provisions and explain additional policy before organisations commit resources.

What companies need to understand

ACNC charity registration differs from ATO DGR endorsement, which may cover an organisation or a specific fund. Not all charities qualify (Australian Charities and Not-for-profits Commission [ACNC], n.d.).

Check recipient and payment type, governance and authority. Registration does not establish staffing or cash flow.

What patient organisations need to understand

Section 11 supports relationships improving medicine use and health outcomes and relevant non-promotional sharing based on genuine need and expertise (Medicines Australia, 2025).

Agree the role and needed information. Patient expertise does not confer healthcare-professional status; explain restrictions and alternatives.

Communications and transparency

TGA generally prohibits public prescription advertising with limited exceptions and assesses purpose and context (Therapeutic Goods Administration [TGA], 2026).

Edition 20 reports relevant support. Agree classification, in-kind contributions, public descriptions and correction before contracting, including third-party arrangements (Medicines Australia, 2025, sec. 14).

Regulatory and access participation

PBAC invites patient and public comments to inform understanding alongside clinical and economic evidence (Australian Government Department of Health, Disability and Ageing, 2026).

Check agenda and deadline, preserve organisational control and explain methods and support. Logistics assistance should not become control of the submission.

Practical example and local checks

For supported consultation before PBAC, agree methods, accessible participation, privacy and reporting early. Separate the official response from a public campaign; materials suitable for assessment may not be suitable for unrestricted distribution.